Characterization of growth hormone secretagogue small molecule ibutamoren (MK‐0677) and its possible metabolites in thoroughbred horses for doping control

• Published in: Rapid communications in mass spectrometry Vol. 36; no. 18; pp. e9337 - n/a
• Main Authors: Philip, Moses, Karakka Kal, Abdul Khader, Subhahar, Michael Benedict, Karatt, Tajudheen K., Mathew, Binoy, Koshy, Shino Ann
• Format: Journal Article
• Language: English
• Published: Bognor Regis Wiley Subscription Services, Inc 30.09.2022
• Subjects: Analogs; Growth hormones; Liquid chromatography; Mass spectrometry; Metabolites; Oxidation; Peptides; Sulfonic acid
• ISSN: 0951-4198; 1097-0231
• DOI: 10.1002/rcm.9337

Rationale It is important to remember that performance‐enhancing agents such as non‐peptide growth hormone secretagogues present a significant risk of abuse. Ibutamoren (MK‐0677) is a potent, long‐acting, selective non‐peptide growth hormone secretagogue that can be taken orally. Methods This study examines ibutamoren and its metabolites in thoroughbred horses after oral administration. Liquid chromatography/high‐resolution mass spectrometry was used to determine the probable structures of the detected metabolites. Results In this study, 22 metabolites of ibutamoren were identified (17 phase I and 5 phase II). Oxidation of ibutamoren leads to hydroxylated metabolites (mono and di). The study also detected dissociated side chains (benzyl group and 2‐amino‐2‐methylpropanamide) and hydrogenated metabolites. The glucuronic acid conjugated analogs of ibutamoren were detected during phase II of the study, but no sulfonic acid conjugated analogs were observed. The major metabolites can be detected up to 96 hours after a single dose, and ibutamoren can persist for up to 72 hours. Conclusions These findings will aid in the detection of ibutamoren and the detection of its illegal use in competitive sports.